Real-world evidence demonstrates proteinuria reduction and eGFR preservation in IgAN, suggesting treatment benefits.
Finerenone significantly reduced proteinuria and preserved eGFR in patients with IgAN over 12 months, with a favorable safety profile, suggesting potential benefit as an adjunctive treatment, pending randomized controlled trial confirmation. This study provides real-world, hypothesis-generating evidence for finerenone in IgAN, which can inform future RCT design and meta-analyses.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: